Valeant Pharmaceuticals (NYSE: VRX)CEO Joe Papa has said for a while that the company is a great turnaround opportunity. But when the drugmaker reported its 2017 fourth-quarter resultsin February, it was clear that any turnaround wouldn't happen quickly.
Valeant Pharmaceuticals' Turnaround Gains Momentum With a Better-Than-Expected First Quarter
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться